Insider Selling: Lantheus Holdings, Inc. (NASDAQ:LNTH) CAO Sells 341 Shares of Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH) CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $61.24, for a total transaction of $20,882.84. Following the transaction, the chief accounting officer now directly owns 63,239 shares in the company, valued at $3,872,756.36. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Andrea Sabens also recently made the following trade(s):

• On Tuesday, February 13th, Andrea Sabens sold 341 shares of Lantheus stock. The stock was sold at an average price of $55.31, for a total transaction of $18,860.71.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $63.81 on Friday. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $100.85. The stock has a market cap of $4.37 billion, a price-to-earnings ratio of 13.75 and a beta of 0.53. The company’s 50-day moving average price is $60.81 and its 200 day moving average price is $62.97. The company has a current ratio of 5.80, a quick ratio of 5.45 and a debt-to-equity ratio of 0.69.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.33 by $0.26. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. The company had revenue of $354.00 million for the quarter, compared to analysts’ expectations of $350.44 million. As a group, research analysts forecast that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on LNTH shares. B. Riley upped their price target on shares of Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday. Truist Financial reissued a “buy” rating and issued a $82.00 price objective (up from $80.00) on shares of Lantheus in a research note on Monday, February 26th. JMP Securities reissued a “market outperform” rating and issued a $100.00 price objective on shares of Lantheus in a research note on Friday, February 23rd. Finally, StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $104.71.

Institutional Investors Weigh In On Lantheus

Several hedge funds have recently modified their holdings of LNTH. FMR LLC boosted its stake in shares of Lantheus by 198.2% during the 3rd quarter. FMR LLC now owns 2,146,085 shares of the medical equipment provider’s stock worth $149,110,000 after purchasing an additional 1,426,465 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Lantheus by 32.9% during the 1st quarter. Vanguard Group Inc. now owns 5,742,083 shares of the medical equipment provider’s stock worth $317,595,000 after purchasing an additional 1,422,269 shares during the last quarter. Norges Bank acquired a new stake in shares of Lantheus during the 4th quarter worth about $45,379,000. Point72 Asset Management L.P. purchased a new position in shares of Lantheus during the 4th quarter worth about $28,042,000. Finally, Alliancebernstein L.P. lifted its holdings in shares of Lantheus by 18.1% during the 4th quarter. Alliancebernstein L.P. now owns 3,193,302 shares of the medical equipment provider’s stock worth $162,731,000 after acquiring an additional 489,203 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.